TSH-secreting adenoma improved with cabergoline.
TSH-secreting adenomas are rare tumors, representing only 0.5 to 2.5% of pituitary adenomas. Their main clinical characteristics include signs of thyrotoxicosis, diffuse goiter and a compressive syndrome. Biologically, free T4 and T3 serum levels are elevated, contrasting with inadequate serum TSH levels and increased alpha chains. Magnetic resonance (MR) imaging shows a pituitary tumor, the main differential diagnosis being resistance to thyroid hormones. Treatment is based on surgery, possibly associated with somatostatin analogs and radiotherapy. Though the long-term evolution of this rare pathology seems to have improved, some clinical situations are still a challenge to treat. We report one such case that was resistant to both stereotactic radiotherapy and somatostatin analogs, but surprisingly improved with cabergoline. We suggest that cabergoline should be considered as an alternative treatment in cases of pituitary adenomas that resist traditional treatments.
Mouton
F
F
Service d'endocrinologie et métabolisme, CHU de Lille, 6, rue du Pr Laguesse, 59037 Lille cedex, France.
Faivre-Defrance
F
F
Cortet-Rudelli
C
C
Assaker
R
R
Soto-Ares
G
G
Defoort-Dhellemmes
S
S
Blond
S
S
Wemeau
J-L
JL
Vantyghem
M-C
MC
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001842:Bone and Bones / Q000002:abnormalities / Q000473:pathology; D000077465:Cabergoline; D004873:Ergolines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism*; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D000970:Antineoplastic Agents; D004873:Ergolines; D014284:Triiodothyronine; D013972:Thyrotropin; D000077465:Cabergoline; D013974:Thyroxine